Nanomedicine Market Size & Share

1. The global Nano medicine market is projected to grow from $263.68 billion in 2025 to $570.98 billion by 2032, with a compound annual growth rate of 11.7%. North America dominates with a 45.88% market share, driven by increasing chronic disease cases and high numbers of FDA approvals. Key market segments include:  Therapeutics (largest segment): Focused on targeted drug delivery and personalized medicine  Diagnostics: Enables early and precise disease detection  Medical Devices: Covers regenerative medicine and implants Major industry developments:  Moderna partnered with Generation Bio in March 2023 to develop non-viral genetic medicines using cell-targeted lipid nanoparticle delivery systems  Evonik expanded its nanoparticle technologies portfolio in September 2023 with new PLA- PEG copolymers  Bionanosim agreed to build BNS Opthalmics with RAFARM in June 2023 The COVID-19 pandemic had a positive market impact, accelerating research in nano-based vaccines and increasing demand for advanced therapeutics. Leading companies include Pfizer Inc., Janssen Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd., who focus on strategic partnerships and product development to maintain market position. Key growth drivers include:  Rising prevalence of chronic diseases  Increasing demand for targeted drug delivery systems  Growing adoption of personalized medicine approaches Report: Fortune Business Insights - Nanomedicine Market Size, Share & Trends | Growth [2032] https://www.fortunebusinessinsights.com/nanomedicine-market-110983